Andrew S Poklepovic

12PUBLICATIONS
108CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular medicinePredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 10, 2026
Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).

Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan

|Feb 11, 2026
Durable disease control of adult-onset xanthogranuloma with time-limited mitogen-activated extracellular kinase inhibition: a case report.

Hyun Lee, Ellie McCabe, Thuy Ho

|Feb 03, 2026
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

George Ansstas, Karam Khaddour, Sumedha Sudhaman

|May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.

Dan P Zandberg, Jacob B Allred, Ari J Rosenberg

|Dec 12, 2024
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.

Lilian T Gien, Zihe Song, Andrew Poklepovic

|Oct 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Young Kwang Chae, Megan Othus, Sandip Pravin Patel

Pageof 2

Frequent Collaborators

2 joint publications

Jason J Luke

2 joint publications

Michael Krainock

2 joint publications

Griffin L Budde

1 joint publications

Craig L Slingluff